This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds purchasers of Nu Skin Enterprises, Inc. (NYSE:NUS) (“Nu Skin” or “the Company”) stock who purchased between Oct. 25, 2011 and Jan. 16, 2014 (the “Class Period”) that the deadline to file as a lead plaintiff is March 24, 2014. Investors who suffered significant financial losses related to the case can email
NUS@hbsslaw.com for more information.
Three lawsuits have now been filed in the Utah District Court alleging that Nu Skin made false or misleading representations to investors regarding its business in China, and risks to its business. These cases will likely be consolidated into one case. If you bought stock in the Company during the Class Period, have significant losses in excess of $100,000 and wish to serve as a lead plaintiff in these cases, please contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000. Additional information is available at
In a recent release regarding fourth-quarter results, Nu Skin CFO Ritch Wood said, “We are early in the process of understanding the impact of recent events in China on our business, so it is difficult to project how reflective anticipated first quarter results will be of results for the remainder of the year.”
After a disappointing outlook from the report, the company’s stocks have continued to fall as much as 13 percent.
“The decrease in projected revenue versus our first-quarter guidance provided last November is primarily a result of the recent measures we have taken in China, slightly lower than anticipated revenue increases in other markets, and an anticipated impact of about $20 million associated with the reclassification of a small percentage of selling expenses,” Wood said recently in a release. “In addition, our first-quarter revenue guidance anticipates a four percent negative impact from foreign currency fluctuations.”